CancerNetwork Members: Login | Register
    
 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Join us on
LinkedIn
Sign up for our
Newsletters
Subscribe to our
RSS Feed

 

Order Your Copy!
(2010, 13th Edition)

 


 

Please allow 3 – 4 weeks to ship

Essentials for Tailoring Multiple Myeloma Therapy
 
ONCOLOGY: March 2010 Volume 24 Number 3 Supplement 2

Essentials for Tailoring Multiple Myeloma Therapy
Supported by an educational grant from Millennium Pharmaceuticals, Inc.
Historically, multiple myeloma, the second most common hematologic malignancy in the US, has been  difficult to manage. Hematologists/oncologists are more likely to encounter patients with myeloma, as an analysis of population-based cancer registries in nine countries indicates that the burden (number of incident cases) of this disease has increased. The three articles in this supplement discuss tailoring initial treatment for newly diagnosed myeloma patients who are eligible for transplantation; emerging induction therapies and newer regimens for newly diagnosed patients who will not undergo transplant; and tailoring treatment for patients with relapsed/refractory myeloma, including clinical data on NCCN-recommended therapies.
To view general information, please click here.
 
Myeloma Supplement Articles

Introduction: Essentials for Tailoring Multiple Myeloma Therapy
March 10, 2010

Hematologists/oncologists and other physicians can expect to encounter an increasing number of patients with multiple myeloma in the coming years. Between 1997 and 2006, the incidence rate of myeloma declined in the United States, but the burden (the number of incident cases) increased.

Tailoring Treatment for Multiple Myeloma Patients With Relapsed and Refractory Disease
March 8, 2010

Although prognostic factors in the context of relapsed and refractory disease require further characterization, high-risk patients include those with certain cytogenetic abnormalities, high β2-microglobulin, and low serum albumin.

Best Practices in the Management of Newly Diagnosed Multiple Myeloma Patients Who Will Not Undergo Transplant
March 8, 2010

No survival advantage of autologous stem cell transplantation (ASCT) has been documented for patients older than 65 years, and in the era of thalidomide (Thalomid), bortezomib (Velcade), and len­alidomide (Revlimid), ASCT has a diminished role in the front-line treatment of older patients with myeloma.

Tailoring Initial Treatment for Newly Diagnosed, Transplantation-Eligible Multiple Myeloma
March 8, 2010

High-dose melphalan (Alkeran) and autologous stem cell transplantation are commonly incorporated into the initial line of therapy for patients newly diagnosed with multiple myeloma.